Gleamer has raised $40.0M in total across 3 funding rounds.
Gleamer's investors include Cipio Partners, XAnge, Michael Benabou.
Gleamer is a Paris-based medical technology company founded in 2017 that develops AI-powered solutions for radiology, primarily through its Gleamer Copilot® platform. This unified AI suite assists radiologists in analyzing medical images across modalities like X-rays, CT scans, mammography, and expanding into MRI, detecting abnormalities such as fractures and lesions to boost diagnostic accuracy, speed up workflows, and prioritize urgent cases[1][2][3][5]. Deployed in over 2,500 clinical sites across 45+ countries, it processes 35-45 million exams annually, serving public and private institutions to reduce healthcare costs, standardize care in underserved areas, and improve patient outcomes[1][5]. With $38M+ in funding, strong clinical validation (30+ publications, 80 studies), and partnerships like Google Cloud and Konica Minolta, Gleamer shows robust growth momentum via geographic expansion and product diversification[1][6].
Gleamer emerged in 2017 in France from a team of medical doctors, engineers, and data scientists who recognized AI's potential to address radiology's growing demands amid radiologist shortages[1][3][4]. Christian Allouche serves as CEO, with Alexis Ducarouge as CTO, driving the vision to make high-quality diagnostics accessible, especially in medical deserts[1][3]. The idea stemmed from deep learning algorithms trained on vast image datasets to spot subtle abnormalities humans might miss, quickly gaining traction with certified products for standard radiology and rapid adoption in Europe and the US[1][2]. Pivotal moments include early deployment in 2,500+ institutions and recent acquisitions of Pixyl and Caerus Medical in 2024 to enter MRI, alongside $29.5M in recent funding[1][6].
Gleamer stands out in the crowded radiology AI market through these key strengths:
Gleamer rides the AI-in-healthcare wave, capitalizing on radiology's acute challenges: global radiologist shortages, rising imaging volumes, and demands for precision in underserved regions[1]. Timing aligns with regulatory approvals (FDA-cleared tools) and post-pandemic workflow pressures, amplified by foundation models enabling multi-modality analysis amid a market projected for rapid AI adoption[1][5]. Favorable forces include falling AI compute costs, vast unlabeled imaging data for training, and payer incentives for cost-saving diagnostics. Gleamer influences the ecosystem by standardizing care quality, fostering AI trust via evidence (publications, adoptions), and enabling "medical deserts" access, positioning it as a leader in equitable, scalable radiology AI[1][3].
Gleamer is poised for accelerated growth by completing its modality suite (MRI imminent post-acquisitions) and deepening US/Europe penetration, potentially doubling exam volumes via more partnerships and foundation model upgrades[1][5][6]. Trends like multimodal AI integration, real-world evidence databases, and regulatory harmonization will propel it, while competition from players like Subtle Medical tests execution. Its influence may evolve from pioneer to platform standard, empowering global radiology equity and tying back to its core mission: AI that makes elite diagnostics ubiquitous for faster, fairer patient care[1][3].
Gleamer has raised $40.0M across 3 funding rounds. Most recently, it raised $29.0M Series B in June 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2023 | $29.0M Series B | Cipio Partners, XAnge, Michael Benabou | |
| Sep 1, 2020 | $9.0M Series A | Cipio Partners, XAnge, Michael Benabou | |
| Jul 1, 2018 | $2.0M Seed | Cipio Partners, XAnge, Michael Benabou |
